Harlan Robins, PhD, is a distinguished scientist and the Chief Scientific Officer at Adaptive Biotechnologies Corp, a company focused on revolutionizing the diagnosis and treatment of diseases through immune system profiling. Dr. Robins holds a Bachelor's degree in Physics from Harvard University and a PhD in Physics from the Massachusetts Institute of Technology (MIT). His academic journey laid a strong foundation for his career in biotechnology, where he has made significant contributions to the field of immunosequencing. Before joining Adaptive Biotechnologies, Dr. Robins conducted groundbreaking research at the Fred Hutchinson Cancer Research Center, where he developed novel methods for analyzing T-cell and B-cell receptors. His work in this area has been pivotal in advancing the understanding of the immune system's role in disease. At Adaptive Biotechnologies, Dr. Robins leads the scientific team in developing innovative technologies that enable the detection and monitoring of minimal residual disease (MRD) and the identification of neoantigens for personalized cancer therapies. Under his leadership, the company has achieved several milestones, including the development of clonoSEQ, a highly sensitive test for MRD in blood cancers. In addition to his role at Adaptive Biotechnologies, Dr. Robins is an active member of the scientific community, with numerous publications in prestigious journals and several patents to his name. His work continues to push the boundaries of what is possible in immune system analysis, and his leadership is instrumental in driving Adaptive Biotechnologies' mission to improve patient outcomes through cutting-edge research and technology.